Proteome-Wide Mapping and Reverse Vaccinology Approaches to Design a Multi-Epitope Vaccine against Clostridium perfringens
| Autor: | Khaled S Allemailem, Usman Ali Ashfaq, Amna Abrar, Sehar Aslam, Samman Munir, Fahad M. Aldakheel, Mohsin Khurshid |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Antigenicity
Clostridium perfringens medicine.medical_treatment In silico Immunology Computational biology Biology medicine.disease_cause Article Epitope Antigen Drug Discovery medicine sub-unit vaccine Pharmacology (medical) Pharmacology Immunogenicity subtractive proteomics Reverse vaccinology molecular docking immuno-iformatics Infectious Diseases Medicine Adjuvant |
| Zdroj: | Vaccines Volume 9 Issue 10 Vaccines, Vol 9, Iss 1079, p 1079 (2021) |
| ISSN: | 2076-393X |
| Popis: | C. perfringens is a highly versatile bacteria of livestock and humans, causing enteritis (a common food-borne illness in humans), enterotoxaemia (in which toxins are formed in the intestine which damage and destroy organs, i.e., the brain), and gangrene (wound infection). There is no particular cure for the toxins of C. perfringens. Supportive care (medical control of pain, intravenous fluids) is the standard treatment. Therefore, a multiple-epitope vaccine (MEV) should be designed to battle against C. perfringens infection. Furthermore, the main objective of this in silico investigation is to design an MEV that targets C. perfringens. For this purpose, we selected the top three proteins that were highly antigenic using immuno-informatics approaches, including molecular docking. B-cells, IFN-gamma, and T cells for target proteins were predicted and the most conserved epitopes were selected for further investigation. For the development of the final MEV, epitopes of LBL5, CTL17, and HTL13 were linked to GPGPG, AAY, and KK linkers. The vaccine N-end was joined to an adjuvant through an EAAK linker to improve immunogenicity. After the attachment of linkers and adjuvants, the final construct was 415 amino acids. B-cell and IFN-gamma epitopes demonstrate that the model structure is enhanced for humoral and cellular immune responses. To validate the immunogenicity and safety of the final construct, various physicochemical properties, and other properties such as antigenicity and non-allergens, were evaluated. Furthermore, molecular docking was carried out for verification of vaccine compatibility with the receptor, evaluated in silico. Also, in silico cloning was employed for the verification of the proper expression and credibility of the construct. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|